Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
ALK-abello is a Danish pharmaceutical company dedicated to researching and developing innovative allergy treatment solutions. As a global leader in allergen immunotherapy (AIT), the company sustainably improves the quality of life for allergy sufferers.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
ALK-abello is scheduled to report its next quarterly earnings on 11/17/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
ALK-abello last reported quarterly earnings on 8/20/2026 (Q2 2026). Earnings per share (EPS) came in at 1.50 DKK.
Across its last 3 earnings reports, ALK-abello stock moved by ±3.5% on average the following day. The largest reaction was +7% on 05/04/2026; 2 of 3 reactions were positive.
ALK-abello has beaten analyst EPS estimates in 1 of its last 3 evaluated quarters (beat rate: 33.3%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 3 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.